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Letters to the Editor
GROUP SEQUENTIAL METHODS
SIR,-The publication of any paper in-
tended to reduce the disparity between the
theory and practice of (cancer) clinical trial
design and analysis is to be wAelcomed. Stuart
Pocock's survey of the current practice of
clinical trials (Br. J. Cancer (1978) 38, 757)
indicates that studies involving insufficient
subjects or using inappropriate methods of
analysis are common. This will come as no
surprise to many medical statisticians work-
ing in the field.
The "group sequential methods" w%Nhich
he advocates represent a direct attempt to
match theory to common practice. Further
development of group sequential techniques
for use with appropriate non-parametric
methods ofsurvival data analysis (such as the
logrank test) would be welcome.
Unfortunately, in presenting his case for
the use of group sequential methods, Dr
Pocock seeks to demonstrate (p. 757) "a
sharp contrast between the theoretical ideal
ofsequential methods and the practical situa-
tion of cancer clinical trials". Whilst strong
assumptions may have been necessary for the
valid application of (conventional) sequential
methods at earlier stages in their develop-
ment, more recent contributions have allowed
considerable relaxation of these restrictions.
For example, Cox (1963) and Whitehead
(1978) greatly extend the class ofdistributions
to which sequential methods may be applied.
and sequential forms of the logrank and
Wilcoxon tests described by Jones and
Whitehead (1979) do not require patients to
be entered in matched pairs or patient evalua-
tion to be instantaneous. Of course, if the
delay before evaluation is not fairly short
relative to the recruitment period ofthe trial,
there will be insufficient feedback of trial
progress to w-arrant use of any sequential
method. Group sequential methods do assume
aregular, ratherthancontinuous, examination
of the data, although only a very strict inter-
pretation of conventional methods would
render this a problem.
The calculations involved in the use of the
sequential, logrank and Wilcoxon tests can
be carried out using computer programs with
12
wihich many clinical trials organisers will
already be familiar (for example by using the
logrank program referred to by Peto et al.,
1977). Thus, it remains to be demonstrated
that conventional sequential analysis is
necessarily a more exhausting exercise than
use of "group sequential" methods, especially
if, as Dr Pocock's survey suggests, the median
accrual rate of patients into cancer clinical
trials is only 33 per annum.
25 January 1979
D. R. JONES
Department ofCommunity Medicine,
Westminster Medical School
J. WrHITEHEAD
Department ofApplied Statistics,
University ofReading
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SIR,-I am grateful to Drs Jones and
Whitehead for pointing out their recent work
in sequential methods, w%hich provides a
major theoretical advance in this area, since
the need for patients to enter in matched pairs
is removed and the sequential analysis of
survival data is made possible. I feel it would
be very useful iftheir wNAork could be extended
in a more practical direction with a less
mathematical emphasis, so that the medical
statisticians and clinicians responsible for
organizing actual trials can assess its applic-
ability.
It is my experience that conventional
sequential methods are hardly ever used in
clinical trials, the reasons being (1) theoretical
limitations, (2) lack of understanding by trialLETTERS TO THE EDITOR
organizers and (3) the practical infeasibility
of maintaining a constant vigil over accumu-
lating data and taking prompt action when a
sequential boundary is crossed. Drs Jones
and Whitehead have largely removed the first
of these problems, the second could be im-
proved, but I fear the third is liable to remain
an insuperable difficulty. In any trial there
are inevitable delays and errors arising in both
the reporting of patient evaluations by
investigators and their subsequent processing
by the statistical centre, if one exists. There-
fore, one's data are not usually in sufficiently
good order for any continuous sequential
analysis, and it strikes me as more efficient
and reliable to make a special effort every
few months at getting all patient evaluations
up-to-date, correct and ready for analysis.
Also, it is a common and sensible practice
for decisions regarding the stopping or altera-
tion of a clinical trial to be made by a com-
mittee of trial organizers meeting at periodic
intervals to assess the results so far. The
development of group sequential designs puts
this approach on a sound statistical footing.
I do not kno-w of any cancer clinical trial
-which has correctly implemented a conven-
tional sequential design, and therefore suggest
that, fascinating though they are in the de-
velopment of statistical theory, such pro-
cedures may unfortunately have a rather
limited future in practice.
13 February 1979
S. J. POCOCK
Department of Clinical Epidemiology and
Social Medicine,
Roval Free Hospital School of Medicine
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